← Eichor
Study identifier: NCT06435897 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells

Condition: Autoimmune Diseases  ·  Sponsor: Shenzhen Geno-Immune Medical Institute

PhasePhase 1/Phase 2
Planned participants30
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The purpose of this study is to assess the feasibility, safety and efficacy of mesenchymal stem cells (MSCs) in combination with CAR-T cells in treating autoimmune disease. Another goal of the study is to learn more about the safety and function of the MSCs combined with CAR-T cells and their long term effects in autoimmune disease patients.

This description comes directly from the study's public registry record.

Talk to the study team

Lung-Ji Chang, PhD  ·  +86 0755-86573763  ·  c@szgimi.org

Always discuss trial participation with your own doctor first.

Locations (1)

Shenzhen Geno-immune Medical InstituteShenzhen, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06435897